This indicates that the cancer may respond to HER2-targeted therapies. Dr. Gerber says she would recommend Enhertu for any patient with an IHC score of 2+ or higher. “If they don’t express ...

Breast cancer classed as HER2-positive - defined as an immunohistochemical (IHC) score of three or more – accounts for somewhere between 20% to 25% of all patients with the disease. However ...

Assessment of HER2 is recommended in every newly diagnosed case of breast cancer. Immunohistochemistry is the primary option, as long as the cases classified as 2+ or equivocal are re-evaluated by ...

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

Breast cancer classed as HER2-positive – defined as an immunohistochemical (IHC) score of three or more – accounts for somewhere between 20% to 25% of all patients with the disease.

Among patients with human epidermal growth factor receptor 2 (HER2, IHC 3+ or IHC 2+/ISH+) positive unresectable and/or metastatic gastric or gastroesophageal cancer, Enhertu (trastuzumab deruxtecan) ...

The drug is now cleared for use in adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining ...

Approval stipulates use in unresectable or metastatic cases, with HER2 positivity defined as an immunohistochemistry (IHC) score of 3+. According to drugmaker Jazz Pharmaceuticals, the antibody ...